Variant-Sequence Transthyretin (Isoleucine 122) in Late-Onset Cardiac Amyloidosis in Black Americans
Daniel R. Jacobson, M.D., Raymond D. Pastore, M.D., Robert Yaghoubian, M.D., Immaculata Kane, M.S., Gloria Gallo, M.D., Francis S. Buck, M.D., and Joel N. Buxbaum, M.D.
Background After the age of 60, isolated cardiac amyloidosisis four times more common among blacks than whites in the UnitedStates; 3.9 percent of blacks are heterozygous for an amyloidogenicallele of the normal serum carrier protein transthyretin inwhich isoleucine is substituted for valine at position 122 (Ile122). We hypothesized that the high prevalence of transthyretinIle 122 is at least partially responsible for the increasedfrequency of senile cardiac amyloidosis among blacks.
Methods Paraffin blocks of cardiac tissue were obtained froman earlier study of 52,370 autopsies in Los Angeles and wereexamined by immunohistochemical and DNA analyses. Samples wereavailable from 32 of 55 blacks and 20 of 78 whites over 60 yearsof age with isolated cardiac amyloidosis and from two controlgroups (228 cases).
Results Transthyretin amyloidosis was identified in 31 of the32 cardiac-tissue samples from the black patients and in 19of the 20 samples from the white patients. Six of the 26 analyzableDNA samples (23 percent) from the black patients and none ofthe 19 samples from the white patients were heterozygous forthe Ile 122 variant. Four of 125 DNA samples obtained at autopsy(3.2 percent) from a second, more recent, age-matched cohortof blacks without amyloidosis at the same institution were heterozygousfor the transthyretin Ile 122 allele. On reexamination the cardiactissue from these four patients contained small amounts of amyloidnot detected at the initial autopsies. All subjects with theIle 122 variant had ventricular amyloid.
Conclusions The assessment of elderly black patients with unexplainedheart disease should include a consideration of transthyretinamyloidosis, particularly that related to the Ile 122 allele.
Source Information
From the Research Service, New York Veterans Affairs Medical Center, New York (D.R.J., R.D.P., R.Y., I.K., J.N.B.); the Departments of Medicine (D.R.J., J.N.B.) and Pathology (G.G., J.N.B.), New York University School of Medicine, New York; and the Department of Pathology, Los Angeles CountyUniversity of Southern California Medical Center, Los Angeles (F.S.B.).
Address reprint requests to Dr. Buxbaum at the Research Service, New York Veterans Affairs Medical Center, 423 East 23rd St., New York, NY 10010.
Comenzo, R. L.
(2009). How I treat amyloidosis. Blood
114: 3147-3157
[Abstract][Full Text]
Feng, D., Syed, I. S., Martinez, M., Oh, J. K., Jaffe, A. S., Grogan, M., Edwards, W. D., Gertz, M. A., Klarich, K. W.
(2009). Intracardiac Thrombosis and Anticoagulation Therapy in Cardiac Amyloidosis. Circulation
119: 2490-2497
[Abstract][Full Text]
Steward, R. E., Armen, R. S., Daggett, V.
(2008). Different disease-causing mutations in transthyretin trigger the same conformational conversion. Protein Eng Des Sel
21: 187-195
[Abstract][Full Text]
Taylor, M. R.G., Slavov, D., Ku, L., Di Lenarda, A., Sinagra, G., Carniel, E., Haubold, K., Boucek, M. M., Ferguson, D., Graw, S. L., Zhu, X., Cavanaugh, J., Sucharov, C. C., Long, C. S., Bristow, M. R., Lavori, P., Mestroni, L., for the Familial Cardiomyopathy Registry and the B,
(2007). Prevalence of Desmin Mutations in Dilated Cardiomyopathy. Circulation
115: 1244-1251
[Abstract][Full Text]
Jacob, E. K., Edwards, W. D., Zucker, M., D'Cruz, C., Seshan, S. V., Crow, F. W., Highsmith, W. E.
(2007). Homozygous Transthyretin Mutation in an African American Male. J. Mol. Diagn.
9: 127-131
[Abstract][Full Text]
Dember, L. M.
(2006). Amyloidosis-Associated Kidney Disease. J. Am. Soc. Nephrol.
17: 3458-3471
[Abstract][Full Text]
Shah, K. B., Inoue, Y., Mehra, M. R.
(2006). Amyloidosis and the heart: a comprehensive review.. Arch Intern Med
166: 1805-1813
[Abstract][Full Text]
Comenzo, R. L., Zhou, P., Fleisher, M., Clark, B., Teruya-Feldstein, J.
(2006). Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood
107: 3489-3491
[Abstract][Full Text]
Buxbaum, J., Jacobson, D. R., Tagoe, C., Alexander, A., Kitzman, D. W., Greenberg, B., Thaneemit-Chen, S., Lavori, P.
(2006). Transthyretin V122I in African Americans With Congestive Heart Failure. J Am Coll Cardiol
47: 1724-1725
[Full Text]
Engel, W. K., Askanas, V.
(2006). Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects. Neurology
66: S20-S29
[Abstract][Full Text]
Lindqvist, P., Olofsson, B.O., Backman, C., Suhr, O., Waldenstrom, A.
(2006). Pulsed tissue Doppler and strain imaging discloses early signs of infiltrative cardiac disease: A study on patients with familial amyloidotic polyneuropathy. Eur J Echocardiogr
7: 22-30
[Abstract][Full Text]
Holmgren, G, Hellman, U, Lundgren, H-E, Sandgren, O, Suhr, O B
(2005). Impact of homozygosity for an amyloidogenic transthyretin mutation on phenotype and long term outcome. J. Med. Genet.
42: 953-956
[Abstract][Full Text]
Green, N. S., Foss, T. R., Kelly, J. W.
(2005). Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis. Proc. Natl. Acad. Sci. USA
102: 14545-14550
[Abstract][Full Text]
Falk, R. H.
(2005). Diagnosis and Management of the Cardiac Amyloidoses. Circulation
112: 2047-2060
[Full Text]
Dember, L. M., Shepard, J.-A. O., Nesta, F., Stone, J. R.
(2005). Case 15-2005 - An 80-Year-Old Man with Shortness of Breath, Edema, and Proteinuria. NEJM
352: 2111-2119
[Full Text]
Kholova, I, Niessen, H W M
(2005). Amyloid in the cardiovascular system: a review. J. Clin. Pathol.
58: 125-133
[Abstract][Full Text]
Kwong, R. Y., Falk, R. H.
(2005). Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation
111: 122-124
[Full Text]
Reixach, N., Deechongkit, S., Jiang, X., Kelly, J. W., Buxbaum, J. N.
(2004). Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. USA
101: 2817-2822
[Abstract][Full Text]
Askanas, V., Engel, W. K., McFerrin, J., Vattemi, G.
(2003). Transthyretin Val122Ile, accumulated A{beta}, and inclusion-body myositis aspects in cultured muscle. Neurology
61: 257-260
[Abstract][Full Text]
Hammarstrom, P., Jiang, X., Hurshman, A. R., Powers, E. T., Kelly, J. W.
(2002). Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity. Proc. Natl. Acad. Sci. USA
99: 16427-16432
[Abstract][Full Text]
Gertz, M. A.
(2002). Diagnosing Primary Amyloidosis. Mayo Clin Proc.
77: 1278-1279
Lachmann, H. J., Booth, D. R., Booth, S. E., Bybee, A., Gilbertson, J. A., Gillmore, J. D., Pepys, M. B., Hawkins, P. N.
(2002). Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis. NEJM
346: 1786-1791
[Abstract][Full Text]
Gribbin, G M, Gilbertson, J A, Hawkins, P N
(2002). Diagnosis of amyloidosis by histological examination of subcutaneous fat sampled at the time of pacemaker implantation. Heart
87: e7-7
[Abstract][Full Text]
Chakrabartty, A.
(2001). Progress in transthyretin fibrillogenesis research strengthens the amyloid hypothesis. Proc. Natl. Acad. Sci. USA
98: 14757-14759
[Full Text]
Jiang, X., Buxbaum, J. N., Kelly, J. W.
(2001). The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad. Sci. USA
98: 14943-14948
[Abstract][Full Text]
Khan, M F, Falk, R H
(2001). Amyloidosis. Postgrad. Med. J.
77: 686-693
[Abstract][Full Text]
White, J. T., Kelly, J. W.
(2001). Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity invitro. Proc. Natl. Acad. Sci. USA
10.1073/pnas.241406698v1
[Abstract][Full Text]
Purkey, H. E., Dorrell, M. I., Kelly, J. W.
(2001). Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. USA
98: 5566-5571
[Abstract][Full Text]
Hund, E., Linke, R. P., Willig, F., Grau, A.
(2001). Transthyretin-associated neuropathic amyloidosis: Pathogenesis and treatment. Neurology
56: 431-435
[Abstract][Full Text]
Gillmore, J D, Booth, D R, Pepys, M B, Hawkins, P N
(1999). Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart
82
: e2-e2
[Abstract][Full Text]
Peterson, S. A., Klabunde, T., Lashuel, H. A., Purkey, H., Sacchettini, J. C., Kelly, J. W.
(1998). Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl. Acad. Sci. USA
95: 12956-12960
[Abstract][Full Text]
Comenzo, R. L., Vosburgh, E., Falk, R. H., Sanchorawala, V., Reisinger, J., Dubrey, S., Dember, L. M., Berk, J. L., Akpek, G., LaValley, M., O'Hara, C., Arkin, C. F., Wright, D. G., Skinner, M.
(1998). Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood
91: 3662-3670
[Abstract][Full Text]
Dhodapkar, M., Barlogie, B., Gertz, M., Jacobson, D. R., Gallo, G., Buxbaum, J. N., Mahmoud, S., Falk, R. H., Comenzo, R. L., Skinner, M.
(1998). The Systemic Amyloidoses. NEJM
338: 264-265
[Full Text]
Falk, R. H., Comenzo, R. L., Skinner, M.
(1997). The Systemic Amyloidoses. NEJM
337: 898-909
[Full Text]
Benson, M. D.
(1997). Aging, Amyloid, and Cardiomyopathy. NEJM
336: 502-504
[Full Text]
White, J. T., Kelly, J. W.
(2001). Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity invitro. Proc. Natl. Acad. Sci. USA
98: 13019-13024
[Abstract][Full Text]